ClinicalTrials.gg
CompletedNCT05150587Updated Apr 24, 2024Results posted

Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea

A Phase 2 interventional study of Rifaximin and Placebo in Papulopustular Rosacea, sponsored by Alfasigma S.p.A.. Completed at 38 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-24.

Sponsored by Alfasigma S.p.A. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
216
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 145 studies in Rosacea with a site in United States — 8 open to participants now, 9 under way, none of them phase 3. Rosacea · United States.

Enrollment
41st of 137
216 · median 78
Started
2021
with 6 others
Phase 2
35 of 145
4 open now
Registered
124th of 145
by date

Among the 145 studies in Rosacea with a site in United States, this one is the 41st largest by enrollment of the 137 interventional ones that give a count, is one of 7 that started in 2021, is one of 35 in phase 2, and was the 124th registered.

Rosacea

233 studies on the registry are indexed under Rosacea; 23 are open to participants now.

Browse Rosacea studies →

Open to participants now

8 of the 145 studies in Rosacea with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Rosacea studies recruiting now, 9 (53%) set no upper age limit and 7 (41%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 145 studies in Rosacea with a site in United States, or all of them as a file.
02

Study summary

Rosacea is a common chronic inflammatory relapsing-remitting skin condition almost exclusively affecting the central area of the face and the eyes.

Preliminary evidence suggests that treatment with rifaximin, a poorly absorbed oral antibiotic drug may be beneficial in patients with rosacea, particularly in those with papulopustular phenotype and positivity to Lactulose Breath Test (L-BT).

The objective of this study is twofold:

  1. To explore the safety and efficacy of 2 doses of oral Rifaximin versus placebo in adults with moderate-to-severe papulopustular rosacea.
  2. To assess the pharmacokinetics (PK) of these two dose regimens in a sub-group of patients.
03

Conditions studied

  • Papulopustular Rosacea

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Men and women aged 18 years or older at screening.
  • Female participants are eligible if they are: i) of non- or ii) of childbearing potential with a negative pregnancy test result at screening and randomization AND agreeing to use a highly effective method of until 72 hours after taking the last study treatment dose.
  • Presence of rosacea, papulopustular phenotype.
  • Presence of ≥11 and ≤70 facial papules and/or pustules.
  • Moderate or severe rosacea based on Investigator's Global Assessment based on Investigator's judgement.
  • Patients accepting to provide and legally capable of providing free and to all procedures included in the protocol (including the availability to perform a Lactulose Breath Test).

Main Exclusion Criteria:

  • Granulomatous rosacea or rosacea fulminans.
  • Erythematotelangiectatic, phymatous or ocular rosacea only. Patients with these subtypes associated with papulopustular rosacea can be enrolled.
  • Rosacea with Investigator's Global Assessment (IGA) grade ≤2 based on Investigator's judgment.
  • Anticipated need for proctoscopy or colonoscopy within two weeks after lactulose breath test.
  • Subjects requiring a low galactose diet.
  • or intolerance to lactulose or any of the lactulose reparation to be used for L-BT.
  • History of inflammatory bowel disease (Crohn's disease or ulcerative colitis) or other conditions characterized by severe intestinal ulcers.
  • History of coeliac disease.
  • Patients with intestinal obstruction or partial intestinal obstruction.
  • Presence of diarrhoea associated with fever and/or blood in the stool.
  • Severe kidney impairment (i.e. estimated \<30 ml/min).
  • Severe hepatic impairment (i.e. B or C).
  • Cancer or any cancer-related treatment within 5 years prior to screening (excluding non-melanoma skin-cancer).
  • History of alcohol or drug abuse within a year prior to screening, based on Investigator's judgement.
  • Facial skin conditions that can interfere with reliable assessment of rosacea throughout the study (e.g. facial hair, tattoos, other facial adornments, keloids, hypertrophic scarring, recent facial surgery, excessive sun exposure including use of tanning beds)
  • Any other significant health condition (e.g. cardiovascular, respiratory, renal, hepatic, neurologic, psychiatric, hematologic, oncologic, immune etc.) or non-health condition that in the investigator's judgement may: i) jeopardize the patient's safe participation in the trial or ii) make unlikely the patient's completion of the study or iii) make unlikely the patient's compliance with the study procedures (e.g. highly anticipated need of non-permitted treatments, terminal illness, etc.).
  • History of hypersensitivity to the study drug.
  • Treatment with biologic immunomodulatory and/or drugs (e.g. anti-tumor necrosis factor [TNF] drugs) within 6 months prior to randomization.
  • Treatment with non-biologic immunomodulatory and/or immunosuppressive drugs (e.g. cyclosporine, methotrexate etc.) within 30 days prior to randomization.
  • Treatment with warfarin (or other coumarins) within 14 days prior to randomization.
  • Treatment with niacin within 30 days prior to randomization.
  • Topical facial or systemic antibiotics within 30 days before randomization;
  • Treatment with neomycin or other low-absorbable oral antibiotics within 90 days before randomization.
  • Topical facial, inhaled or systemic within 30 days prior to randomization.
  • Topical facial retinoids within 30 days before randomization.
  • Systemic retinoids within 6 months before randomization.
  • Any other topical or systemic treatment for rosacea within 30 days before randomization (including also laser and pulsed light, etc.).
  • Over-the-counter intestinal or topical skin probiotics (functional food is allowed), within 30 days before randomization.
  • Any experimental treatment within 6 months prior to randomization.
  • Current swab-positive or suspected (under investigation) Covid-19 infection; or fever and one or more of the following respiratory disease signs or symptoms: cough, sputum production, shortness of breath within the last 14 days; or contact with people with Covid-19 infection within the last 14 days.
  • Women who are pregnant, breast-feeding or planning a pregnancy during the trial period.
  • Subjects who are site staff members and their family members, site staff members otherwise supervised by the investigator, or patients who are Alfasigma's employees.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
216 participants (actual)

Study arms

  • Active comparator
    Rifaximin 250 mg TID

    Drug: Rifaximin

  • Active comparator
    Rifaximin 500 mg TID

    Drug: Rifaximin

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Rifaximin tablets

  • DrugPlacebo

    Placebo tablets

06

What researchers measure

Primary outcomes

  1. Co-primary Endpoint: Change From Baseline in Number of Rosacea Inflammatory Lesions

    This is a co-primary endpoint. Success of the study will be declared in any of the active treatment groups if both the co-primary efficacy endpoints (here listed as 1 and 2) will be satisfied (note: the two items may not necessarily occur in the same patient): 1. Mean change from Baseline in number of rosacea inflammatory lesions (papules, pustules or plaques) at the end of treatment; 2. Percent of participants showing treatment success defined as IGA (Investigator's Global Assessment) score of 0 or 1 (0=clear; 1=almost clear; 2=mild; 3=moderate; 4=severe) at the end of treatment.

    Time frame: 30 days

  2. Co-primary Endpoint: Treatment Success Rate

    This is a co-primary endpoint. Success of the study will be declared in any of the active treatment groups if both the co-primary efficacy endpoints (here listed as 1 and 2) will be satisfied (note: the two items may not necessarily occur in the same patient): 1. Mean change from Baseline in number of rosacea inflammatory lesions (papules, pustules or plaques) at the end of treatment; 2. Percent of participants showing treatment success defined as IGA (Investigator's Global Assessment) score of 0 or 1 (0=clear; 1=almost clear; 2=mild; 3=moderate; 4=severe) at the end of treatment.

    Time frame: 30 days

07

Results

Posted Apr 24, 2024

Participant flow

Participant flow — Overall Study
MilestoneRifaximin 250 mg TIDRifaximin 500 mg TIDPlacebo
Started708066
Number of participants included in the "full analysis set"657663
Completed647360
Not completed676

Outcome measures

PrimaryCo-primary Endpoint: Change From Baseline in Number of Rosacea Inflammatory Lesions

This is a co-primary endpoint. Success of the study will be declared in any of the active treatment groups if both the co-primary efficacy endpoints (here listed as 1 and 2) will be satisfied (note: the two items may not necessarily occur in the same patient): 1. Mean change from Baseline in number of rosacea inflammatory lesions (papules, pustules or plaques) at the end of treatment; 2. Percent of participants showing treatment success defined as IGA (Investigator's Global Assessment) score of 0 or 1 (0=clear; 1=almost clear; 2=mild; 3=moderate; 4=severe) at the end of treatment.

Time frame:
30 days
Reported as:
Mean · lesions (rosacea inflammatory)
Co-primary Endpoint: Change From Baseline in Number of Rosacea Inflammatory Lesions
lesions (rosacea inflammatory)Rifaximin 250 mg TIDRifaximin 500 mg TIDPlacebo
Co-primary Endpoint: Change From Baseline in Number of Rosacea Inflammatory Lesions-10.0 ± 9.24-6.7 ± 14.78-9.2 ± 10.49
PrimaryCo-primary Endpoint: Treatment Success Rate

This is a co-primary endpoint. Success of the study will be declared in any of the active treatment groups if both the co-primary efficacy endpoints (here listed as 1 and 2) will be satisfied (note: the two items may not necessarily occur in the same patient): 1. Mean change from Baseline in number of rosacea inflammatory lesions (papules, pustules or plaques) at the end of treatment; 2. Percent of participants showing treatment success defined as IGA (Investigator's Global Assessment) score of 0 or 1 (0=clear; 1=almost clear; 2=mild; 3=moderate; 4=severe) at the end of treatment.

Time frame:
30 days
Reported as:
Number · Percentage of participants
Co-primary Endpoint: Treatment Success Rate
Percentage of participantsRifaximin 250 mg TIDRifaximin 500 mg TIDPlacebo
Co-primary Endpoint: Treatment Success Rate9.23 (2.19 to 16.27)9.21 (2.71 to 15.71)11.11 (3.35 to 18.87)

Adverse events

Collected over Up to 60 days. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rifaximin 250 mg TID0/70 (0%)0/70 (0%)8/70 (11.4%)
Rifaximin 500 mg TID0/80 (0%)0/80 (0%)17/80 (21.3%)
Placebo0/66 (0%)0/66 (0%)12/66 (18.2%)
Most frequent other events
Most frequent other events
EventRifaximin 250 mg TIDRifaximin 500 mg TIDPlacebo
headacheNervous system disorders4/704/802/66
Abdominal painGastrointestinal disorders0/704/802/66
ConstipationGastrointestinal disorders1/703/802/66
NauseaGastrointestinal disorders1/701/802/66
Influenza like illnessGeneral disorders0/701/802/66
Abdominal distensionGastrointestinal disorders2/702/801/66
DiarrhoeaGastrointestinal disorders0/702/801/66

Baseline characteristics

Baseline analysis is based on the Full Analysis Set

Age, Categorical
Age, Categorical(Participants)Rifaximin 250 mg TIDRifaximin 500 mg TIDPlaceboTotal
<=18 years0000
Between 18 and 65 years586754179
>=65 years79925
Sex: Female, Male
Sex: Female, Male(Participants)Rifaximin 250 mg TIDRifaximin 500 mg TIDPlaceboTotal
Female525444150
Male13221954
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Rifaximin 250 mg TIDRifaximin 500 mg TIDPlaceboTotal
American Indian or Alaska Native2002
Asian0000
Native Hawaiian or Other Pacific Islander0112
Black or African American24612
White596856183
More than one race0000
Unknown or Not Reported2305
08

Study locations

38 sites
  • Dermatology Research Ventures
    Yuma, Arizona 85365, United States
  • Johnson Dermatology
    Fort Smith, Arkansas 72916, United States
  • Long Beach Clinical Trials
    Long Beach, California 90806, United States
  • Metropolis Dermatology
    Los Angeles, California 90017, United States
  • LA Universal Research Center
    Los Angeles, California 90057, United States
  • Cosmetic Laser Dermatology
    San Diego, California 92121, United States
  • UCSD
    San Diego, California 92122, United States
  • University Clinical Trials, Inc.
    San Diego, California 92123, United States
  • Skin Care Research
    Boca Raton, Florida 33486, United States
  • MOORE Clinical Research,Inc.
    Brandon, Florida 33511, United States
  • Sweet Hope Research Specialty, Inc.
    Hialeah, Florida 33016, United States
  • Savin Medical Group
    Miami Lakes, Florida 33014, United States
  • Leavitt Medical Associates of Florida
    Ormond Beach, Florida 32174, United States
  • DelRicht Research
    Marietta, Georgia 30060, United States
  • DS Research
    Clarksville, Indiana 47129, United States
  • Skin Science PLLC
    Louisville, Kentucky 401217, United States
  • DS Research
    Louisville, Kentucky 40241, United States
  • Delricht Research Baton Rouge LA
    Baton Rouge, Louisiana 70809, United States
  • Delricht Research Covington LA
    Covington, Louisiana 70433, United States
  • DelRicht Research Houma Louisiana
    Houma, Louisiana 70360, United States
  • DelRicht Research
    New Orleans, Louisiana 70115, United States
  • Revival Research Institute, LLC.
    Troy, Michigan 48084, United States
  • Grekin Skin Care Institute
    Wyandotte, Michigan 48192, United States
  • MediSearch Clinical Trials
    Saint Joseph, Missouri 65406, United States
  • JDR Dermatology Research
    Las Vegas, Nevada 89148, United States
  • JUVA Skin and Laser Center
    New York, New York 10022, United States
  • Onsite Clinical Solutions
    Charlotte, North Carolina 28277, United States
  • Dermatology Consulting Services, PLLC
    High Point, North Carolina 27262, United States
  • DelRicht Research
    Tulsa, Oklahoma 74114, United States
  • Oregon Dermatology and Research Center
    Portland, Oregon 97210, United States
  • Paddington Testing Co, Inc
    Philadelphia, Pennsylvania 19103, United States
  • Dermatology Treatment and Research Center
    Dallas, Texas 75230, United States
  • 3A Research
    El Paso, Texas 79925, United States
  • DelRicht Research Frisco Texas
    Frisco, Texas 75034, United States
  • Austin Institute for Clinical Research
    Pflugerville, Texas 78660, United States
  • Progressive Clinical Research
    San Antonio, Texas 78213, United States
  • Velocity Clinical Research
    Salt Lake City, Utah 84117, United States
  • West End Dermatology Associates
    Richmond, Virginia 23233, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Oct 2022, 12 months.

Results were first posted in Apr 2024, 1 year 6 months after primary completion.

Of 20 phase 2 interventional studies under Rosacea, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's 12 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2021
First posted
Dec 9, 2021
StartActual
Oct 5, 2021
Primary completionActual
Oct 20, 2022
CompletionActual
Oct 20, 2022
Results first posted
Apr 24, 2024
Last update
Apr 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05150587
Lead sponsor
Alfasigma S.p.A.
Collaborators
bioRASI, LLC
Responsible party
Sponsor
First posted
Dec 9, 2021
Start date
Oct 5, 2021
Primary completion
Oct 20, 2022
Completion
Oct 20, 2022
Results posted
Apr 24, 2024
Last update
Apr 24, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rifaximin

Start the discussion